DGAP-News

aap: Sales in Q4/2016 at EUR 2.4 million and in FY/2016 at EUR 11.2 million; sales growth in established markets and EBITDA improvement planned for FY/2017 - Seite 2

 

FY/2016 Sales

In EUR million	FY/2016	FY/2015	Change on year
Trauma	9.6	10.8	-11%
Other	1.6	1.5	+9%
Sales continued operation	11.2	12.3	-9%
Sales discontinued operation	4.2*	15.7	< -100%
Group sales	15.4*	28.0	-45%

 

*Includes aap Biomaterials GmbH business from 01/01/2016 to 05/11/2016.

aap is looking back on a challenging financial year 2016 in which the financial targets could not be met but nevertheless good progress was made with the implementation of the strategy. In the last year, the company sold its subsidiary aap Biomaterials GmbH and its remaining stake of 33% in aap Joints GmbH, which marked the final steps on the way to a pure player in trauma. In its efforts to focus on established markets, aap also managed to increase the share of sales attributable to North America and Europe together year on year, by around 50% to EUR 6.8 million in financial year 2016 (FY/2015: EUR 4.5 million). Overall, the realized pleasing sales increases in North America and Europe could however not compensate the missing sales contributions from China. Furthermore, delays in the sales development in various markets led to a sales shift in financial year 2017.